# US 2016/0256413 A1 · Composition and method for treating neurological disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256413 A1
- Document ID: US20160256413A1
- Status: Published application
- Kind: A1
- Application number: 14/856,398
- Filed: 2015-09-16
- Published: 2016-09-08
- Earliest claimed: 2004-11-24
- Assignees: Adamas Pharmaceuticals, Inc.
- Applicants: Adamas Pharmaceuticals, Inc.
- Inventors: Gregory T. Went; Timothy J. Fultz; Timothy S. Burkoth
- Web page: https://patentgrep.com/patent/US20160256413A1

## CPC

- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 9/0004: {Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/5021: {Organic macromolecular compounds}
- A61K 9/5047: {Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose}
- A61K 9/5078: {with drug-free core}
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/16: Anti-Parkinson drugs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.

## Claims

### Claim 1

A method comprising:
orally administering to a human subject with Parkinson's disease a once daily dose consisting of (i) 200 to 500 mg of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, and (ii) at least one excipient,
wherein at least one of said excipients is a release modifying excipient, and
wherein at least 50% of said drug is in an extended release form, and
wherein administration of the dose once daily provides a steady state plasma concentration of about 3 μM.

### Claim 2

A method comprising:
orally administering to a human subject with Parkinson's disease a once daily dose consisting of (i) 200 to 500 mg of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, and (ii) at least one excipient,
wherein at least one of said excipients is a release modifying excipient, and
wherein at least 50% of said drug is in an extended release form, and
wherein administration of the dose once daily provides a steady state plasma concentration of about 0.5 μg/ml.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein at least 75% of the drug in the dose is in an extended release form.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein at least 90% of the drug in the dose is in an extended release form.

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein at least some of the drug in the dose is in an immediate release form.

### Claim 6 (depends on 1, 2)

The method of claim 1 or 2, wherein the amount of drug is 300 mg to 500 mg.

### Claim 7 (depends on 1, 2)

The method of claim 1 or 2, wherein the dose is therapeutically effective for the treatment of Parkinson's disease.

### Claim 8 (depends on 1, 2)

The method of claim 1 or 2, wherein the human subject with Parkinson's disease suffers from dyskinesia.

### Claim 9 (depends on 1, 2)

The method of claim 1 or 2, wherein the dyskinesia is levodopa-induced dyskinesia.

### Claim 10 (depends on 1, 2)

The method of claim 1 or 2, additionally comprising administering to the subject a pharmaceutically effective amount of levodopa/carbidopa.

### Claim 11 (depends on 1, 2)

The method of claim 1 or 2, wherein the dose provides a shift in amantadine Tmax of 2 hours to 16 hours relative to an immediate release form of amantadine, wherein the Tmax is measured in a single dose human pharmacokinetic study.

### Claim 12 (depends on 1, 2)

The method of claim 1 or 2, wherein the extended release form comprises an osmotic device which utilizes an osmotic driving force to provide extended release of the drug.

### Claim 13 (depends on 1, 2)

The method of claim 1 or 2, wherein the extent of drug bioavailability is maintained.

### Claim 14 (depends on 1, 2)

The method of claim 1 or 2, wherein the once-daily dose is administered at a therapeutically-effective dose from the onset of therapy.
